Needlestick Prevention Claims Require Support Of Clinical Data, Panel Says
This article was originally published in The Gray Sheet
Clinical data demonstrating efficacy of a sharps injury prevention device should be submitted to FDA in support of any claim, suggestion, or hint that the device reduces the incidence of sharps injury, FDA's General Hospital and Personal Use Devises Advisory Panel concluded.
You may also be interested in...
Release of OSHA's bloodborne pathogen standards will not preclude Congress from addressing legislation in the next session that would require hospitals to use safety needle devices, Capitol Hill staffers say.
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.